Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.4M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
62.1M
-
Shares change
-
+2.17M
-
Total reported value, excl. options
-
$1B
-
Value change
-
+$22.2M
-
Put/Call ratio
-
0.58
-
Number of buys
-
70
-
Number of sells
-
-56
-
Price
-
$16.14
Significant Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q1 2025
153 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock as of Q1 2025.
Spyre Therapeutics, Inc. - Common Stock (SYRE) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.1M shares
.
Largest 10 shareholders include FMR LLC (9.04M shares), Fairmount Funds Management LLC (4.02M shares), RTW INVESTMENTS, LP (3.62M shares), BlackRock, Inc. (3.57M shares), VANGUARD GROUP INC (2.9M shares), Driehaus Capital Management LLC (2.72M shares), VR ADVISER, LLC (2.69M shares), BRAIDWELL LP (2.58M shares), Capital International Investors (2.39M shares), and PERCEPTIVE ADVISORS LLC (2.31M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.